OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CFO exercised or converted 1,112 CYTK derivative securities | OQRO

Home
Insider trades
Cytokinetics
CFO exercised or converted 1,112 CYTK derivative securities

Insider trades

Insider trade

CFO exercised or converted 1,112 CYTK derivative securities

Traded Jul 1, 2026 · Filed Jul 2, 2026

CYTCytokineticsCYTK

1,112
Shares · @ $48.51

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 1, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 2, 2026

CFOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000072
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Jul 2, 2026, 9:17 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Sung Lee

Relationship

Officer

Officer title

EVP, Chief Financial Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jul 1, 2026

Transaction code

Shares / units

1,112

Price per share

$48.51

Acquired / disposed

Acquired (A)

Shares owned after

64,333

Ownership form

Direct

Amendment

Around the same time

Andrew CallosEVP, Chief Commercial Officer

Filed 2mo ago

14KShares · @ $23.26

Traded Jul 30 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Andrew Callos (EVP, Chief Commercial Officer) sold ~$1.12M of Cytokinetics

Planned saleFiled 2mo ago

Andrew CallosEVP, Chief Commercial Officer

Filed 2mo ago

14KDerivative units

Traded Jul 30 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record